Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Philips Healthcare

Operates in Diagnostic Imaging Systems, Patient Care and Clinical Informatics, Customer Services, and Home Healthcare... read more Featured Products: More products

Download Mobile App




Cardiac Troponin Assay Compared with Existing Tests

By LabMedica International staff writers
Posted on 02 May 2017
Efficient rule-out of acute myocardial infarction (MI) in patients presenting with symptoms of cardiac ischemia facilitates early disposition of the patient to outpatient care, and helps to relieve the increasing crowding of the emergency departments (ED) in most hospitals.

Sensitive cardiac troponin (cTn) assays support such a decision based on results at admission and three hours after admission, according to current guidelines. More...
The time needed for results to become available from the hospital central laboratory often delays the disposition decision for another one or two hours.

An international team of scientists collaborating with those at the University of Uppsala compared a novel point-of-care assay (POC) for cardiac troponin I with a high-sensitivity cardiac troponin I laboratory assay. They enrolled 450 prospectively patients admitted with suspected MI at EDs or coronary care units/chest pain units of seven hospitals in Germany, France, Austria and the Netherlands. Patients eligible for enrolment were adults (age ≥ 18 years) who had presented with symptoms suggestive of MI. Only patients who presented for the first time and less than 12 hours from onset of symptom onset were included.

The novel cTnI POC test, the Minicare cTnI, provides a cTnI result within 10 minutes. The test was compared with two widely used cTnI assays: the Abbott Architect hs-cTnI and the POC Abbott I-Stat cTnI. The concentrations of cTnT in lithium-heparin plasma were measured at the local hospital laboratories using a hs-cTnT assay.

The team observed significant correlations for cTnI concentrations measured on the Minicare cTnI, either as whole blood or plasma, compared with the Architect hs-cTnI and I-Stat cTnI. There was evidence of bias for both comparisons: 0.59 (whole blood) and 0.48 (plasma) for the Architect hs-cTnI and 0.48 (whole blood) and 0.43 (plasma) for the I-Stat cTnI. The 8% discordant results among MI patients between Minicare cTnI and Architect hs-cTnI were almost equally distributed with 3% showing elevated concentrations with Minicare cTnI and 5% showing elevated results with Architect hs-cTnI, but non-elevated results with the other.

The authors concluded that that the novel Minicare cTnI POC assay equals the clinical performance in their patient cohort of a hs-cTnI assay. The Minicare cTnI assay, with a very high negative predictive value, may become suitable for prompt and safe rule-out of MI for patients with symptoms suggestive of MI in the emergency setting using a 0/3 hour sampling protocol. The study was published online on March 25, 2017, in the journal Clinica Chimica Acta.


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The blood-based DNA methylation test predicts lymph node metastasis in early-stage gastric cancer (Photo courtesy of Institute of Science Tokyo)

Blood Test to Help Low-Risk Gastric Cancer Patients Avoid Unnecessary Surgery

Accurately identifying lymph node metastasis in early-stage gastric cancer remains a major clinical challenge. CT imaging often misses up to half of lymph node–positive cases, leading clinicians to recommend... Read more

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Microbiology

view channel
Image: The SMART-ID Assay delivers broad pathogen detection without the need for culture (Photo courtesy of Scanogen)

Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples

Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.